Drug intelligence / Profile preview

Keraheal-Allo

Development stage: Unknown
Lead developer: Biosolution
Modality: Cell Therapies
Administration: Topical

Overview

Keraheal-Allo is an allogeneic cell therapy developed by Biosolution (CO Solution) for the treatment of deep second-degree burns. It consists of allogeneic skin-derived keratinocytes formulated in a temperature-sensitive hydrogel. When applied topically to burn wounds, the hydrogel transitions from a liquid to a gel state at body temperature, providing a scaffold for the keratinocytes to promote re-epithelialization and wound healing. The product is approved in South Korea and is covered by workers' compensation insurance.

Brand names: Keraheal-Allo
Other names: 케라힐-알로allogeneic keratinocytes

Beyond the preview

Go deeper on Keraheal-Allo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keraheal-Allo.

Explore the full profile